PeptideCompareTirzepatide — the Mounjaro molecule.
Tirzepatide is the dual GLP-1/GIP receptor agonist approved by the FDA as Mounjaro (diabetes) and Zepbound (obesity). As a research peptide in Europe it is available from multiple EU vendors — understanding the difference between research-grade and pharmaceutical-grade is essential.
- Dual GLP-1 + GIP receptor agonist; the same molecule as the approved medicines Mounjaro (diabetes) and Zepbound (obesity).
- SURMOUNT-1 Phase 3 trial reported up to 22.5% mean body-weight reduction at 72 weeks.
- SURPASS trials showed superior HbA1c reduction versus semaglutide in head-to-head diabetes comparisons.
- Pharmaceutical tirzepatide is EMA-approved and prescription-only in Europe; research-grade powder is a separate, unapproved product category.
- Research-grade material requires reconstitution and COA verification; purity and sterility vary by vendor and batch.
Research peptide vs pharmaceutical Mounjaro
The tirzepatide molecule sold by EU research vendors is the same peptide as Mounjaro/Zepbound. However, pharmaceutical Mounjaro is produced under GMP conditions with rigorous quality controls, specific excipients, sterility testing, and known dosing in pre-filled auto-injectors. Research-grade tirzepatide is a lyophilized powder requiring reconstitution, with purity and sterility that varies by vendor and batch.
What does the research show?
Molecular information
Pharmacokinetics
Potency retained over time
Each line is one storage condition: it starts at 100% and falls as potency is lost. Above the dashed 80% line the material is considered reliable — hover for exact values.
⚠ A structural estimate, derived from each compound's sequence length, cyclisation and oxidation-, deamidation- and light-sensitive residues. Indicative only — not lab-measured per batch.
Compare Tirzepatide prices across EU suppliers
COA-verified · Multiple EU vendors · Updated monthly
Frequently asked questions
What is tirzepatide? ▾
Tirzepatide is a once-weekly peptide that activates two incretin receptors — GLP-1 and GIP. It is the active molecule in the approved medicines Mounjaro (type 2 diabetes) and Zepbound (obesity).
Is research-grade tirzepatide the same as Mounjaro? ▾
It is the same peptide molecule, but not the same product. Mounjaro and Zepbound are made under GMP conditions with sterility testing, defined excipients and pre-filled injectors. Research-grade tirzepatide is a lyophilised powder of variable purity sold for laboratory research only.
Is tirzepatide legal in the EU? ▾
The pharmaceutical (Mounjaro/Zepbound) is EMA-approved and available on prescription. Research-grade tirzepatide is sold as a research chemical for laboratory use and is not a substitute for the approved medicine.
How effective was tirzepatide in trials? ▾
The SURMOUNT-1 trial reported mean weight reductions of roughly 16–22.5% across doses at 72 weeks. In diabetes trials (SURPASS) it produced larger HbA1c reductions than semaglutide in head-to-head comparisons.
How does tirzepatide compare to semaglutide? ▾
Tirzepatide adds GIP receptor activity on top of GLP-1. In direct trials it produced greater weight loss and HbA1c reduction than semaglutide, though individual response varies and side-effect profiles overlap.
What are the common side effects? ▾
Predominantly gastrointestinal — nausea, diarrhoea, vomiting and constipation — usually mild to moderate and most common during dose escalation.
What should I check on a tirzepatide COA? ▾
Look for a batch-matched certificate stating HPLC purity (ideally ≥98%), mass-spec identity, and the testing laboratory's name. Sterility cannot be assumed for research powder.
Should I use research tirzepatide instead of a prescription? ▾
No. If you have a medical indication, the approved pharmaceutical via a physician is the appropriate route. Research-grade material is for laboratory research and is not quality-controlled for human use.
Why do tirzepatide prices vary between EU suppliers? ▾
Vial size, claimed purity and supplier overheads all differ. PeptideCompare normalises this to price per mg so equivalent products can be compared fairly.
References
- SURMOUNT-1 Phase 3 obesity trial reporting up to ~22.5% weight reduction at 72 weeks. Jastreboff AM, et al. N Engl J Med. 2022;387(3):205–216. DOI PubMed 35658024
- SURMOUNT-2 Phase 3 trial in adults with type 2 diabetes and obesity. Garvey WT, et al. Lancet. 2023;402(10402):613–626. DOI PubMed 37385275